ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.

Sector

Manufacturing

Industry

Biological Product (except Diagnostic) Manufacturing

www.admabiologics.com →

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

News

Wall Street Week Ahead

Meet the Red-Hot Artificial Intelligence (AI) Infrastructure Stock That Has Crushed Oracle With 115% Gains in a Year. It Is Still Worth Buying Hand Over Fist.

Gold.com Board Director Sells $1.4 Million Worth of Shares As Gold Has Its Worst Week Since 1983

Prediction: Pivoting Away From Metaverse Will Help Meta's Stock Long Term

3 Genius Artificial Intelligence (AI) Stocks You'll Regret Not Buying Now

LAC Stock Up 32% Over the Past Year But Share Dilution Is Quietly Piling Up

FirstService: Excellent Growth Story Currently On Sale

War and Inflation Are Supposed to Be Gold's Friends. Not This Time.

How Amazon Is Bringing Fast Delivery to Rural America

Best Dividend Stocks to Buy Right Now for Passive Income

China's Sinopec posts 36.8% drop in 2025 net profit on weak petrochemical margins, new energy substitution

2 Magnificent S&P 500 Dividend Stocks Down as Much as 25% to Buy and Hold Forever

Should You Buy Eli Lilly Stock Before April 10?

The Best Stocks to Invest $1,000 in After Last Week's Market Volatility

UCO Is Up 125% This Year but a Hidden Structural Risk Could Erase the Gains

I Was Shocked at Who Is Now Running Berkshire Hathaway's $308 Billion Stock Portfolio

Warren Buffett's Warning to Wall Street Is Echoing Louder Than Ever: 3 Steps Investors Should Take Now

3 High-Yield Dividend Stocks I'd Buy Right Now With No Hesitation

Dauch Corporation Board Director Buys 35,000 Shares After Company Completes Major Acquisition

2 AI Stocks to Buy Before They Soar 80% and 50%, According to Wall Street Analysts

About